Resveratrol reduces inflammatory responses in peripheral blood mononuclear cells from patients with severe asthma.

BACKGROUND

Severe asthma is a chronic inflammatory airway disease frequently associated with neutrophilic inflammation, corticosteroid resistance, and persistent activation of pro-inflammatory signaling pathways, including nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs).

OBJECTIVE

This study aimed to investigate the effects of resveratrol on inflammatory responses in peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects and patients with severe asthma.

MATERIALS AND

METHODS

PBMCs were stimulated with lipopolysaccharide (LPS; 1 µg/mL) for 24 h in the presence or absence of resveratrol (10-4-10-8 M). Cell viability was assessed using the MTT assay, cytokine levels (IL-6, IL-8, and IL-10) were measured by ELISA, and intracellular signaling pathways (NF-κB, ERK1/2, and p38 MAPK) were evaluated by flow cytometry.

RESULTS

Resveratrol did not affect cell viability and significantly reduced IL-6 and IL-8 production in a dose-dependent manner in LPS-stimulated PBMCs, without altering IL-10 levels. Additionally, resveratrol attenuated the phosphorylation of NF-κB, ERK1/2, and p38 MAPK in both monocytes and lymphocytes from healthy individuals and patients with severe asthma.

DISCUSSION AND

CONCLUSION

Resveratrol exerts significant anti-inflammatory effects in human PBMCs by modulating cytokine production and key intracellular signaling pathways associated with severe asthma, suggesting its potential as a complementary therapeutic strategy.